Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IM21 CAR-T in R/R BCMA+ Multiple Myeloma
NCT03711864Phase 1Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Feb 2019
- Primary completion
- Oct 2021
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IM21 in multiple myeloma (MM), sponsored by Peking Union Medical College Hospital. Primary endpoint: Occurrence of study related adverse events at 2 years. Status: unknown.
02
Drugs
IM21
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03711864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03711864.